Home/Pipeline/AN2025S

AN2025S

Not Specified

PreclinicalActive

Key Facts

Indication

Not Specified

Phase

Preclinical

Status

Active

Company

Adlai Nortye

About Adlai Nortye

Adlai Nortye is a clinical-stage biotech focused on developing innovative oncology therapies, with a core strategy of in-licensing and advancing mid-to-late-stage assets into new, high-need indications. Its most advanced candidate, buparlisib (AN2025), is in a pivotal global Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company aims to address significant unmet medical needs by modulating the tumor microenvironment and overcoming resistance to standard treatments like anti-PD-1 therapy.

View full company profile

Therapeutic Areas

Oncology

Other Not Specified Drugs

Drug	Company	Phase	Status
New TCM Formulations	China SXT Pharmaceuticals	Research / Pre-clinical	Development
Long-acting Leronlimab	CytoDyn	Preclinical	Phase in progress
Collaborative Program with Ferring	PharmaBiome	Research	Active
Lighthouse Pilot Product	Cipherome	Pilot	Launched 2020
Nitric Oxide + Collagen Delivery	Jellagen	Research	Active
Undisclosed	Authera	Pre-clinical	Active
mRNA Therapeutics Platform Application	Lupagen	Research	Active
PHYRAGO	Handa Pharmaceuticals	Approved	Active
TASCENSO ODT	Handa Pharmaceuticals	Approved	Active
Axulin	Housey Pharmaceutical Research Laboratories	Commercial	Active
PBI-04711	Phoenix Biotechnology	Pre-clinical	Active
Immunology Program	Ignite Biomedical	Discovery	Active